Kate Haviland

Insider Reports History

Location
Cambridge, MA
Signature
/s/ Douglas Carlson
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Kate Haviland:

Form 4 holding Chief Executive Officer, Director

Blueprint Medicines Corp

Security class
Stock Option (Right to Buy)
Shares / value
0
Estimated value
$2,537,920
Report date
17 Jul 2025
Price
$36.05
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Bicara Therapeutics Inc.

Security class
Common Stock
Shares / value
7,437
Estimated value
$98,491
Report date
12 Sep 2024
Price
$13.24
Ownership
Direct
Form 4 holding Director

Avalyn Pharma Inc.

Security class
Stock Option (Right to Buy)
Shares / value
26,978
Estimated value
Report date
29 Apr 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Kate Haviland

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .